Outlook Therapeutics (OTLK) Non-cash Items (2019 - 2026)

Outlook Therapeutics (OTLK) has 8 years of Non-cash Items data on file, last reported at $3.3 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $3.3 million, down 32.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (down 32.01% YoY), and the FY2025 annual result was $2.0 million, up 3636.13% from the prior year.
• Non-cash Items grew to $3.3 million in Q1 2026 per OTLK's latest filing, from $1.5 million in the prior quarter.
• Over five years, Non-cash Items peaked at $13.6 million in Q3 2023 and troughed at $1200.0 in Q2 2025.
• A 5-year average of $5.6 million and a median of $4.2 million in 2024 frame the typical range for Non-cash Items.
• On a YoY basis, Non-cash Items climbed as much as 3636.13% in 2025 and fell as far as 99.87% in 2025.
• A 5-year view of Non-cash Items shows it stood at $3.3 million in 2022, then soared by 142.11% to $8.0 million in 2023, then fell by 18.68% to $6.5 million in 2024, then tumbled by 77.12% to $1.5 million in 2025, then jumped by 119.69% to $3.3 million in 2026.
• Business Quant data shows OTLK's Non-cash Items at $3.3 million in Q1 2026, $1.5 million in Q4 2025, and $2.0 million in Q3 2025.